Contribution to the concept of polypharmacy I. Etymological notes and characteristics

1. Polypragmoneo. https://slovnik-cizich-slov.abz.cz/web. php/slovo/polypragmoneo

2. Polypragmasy. https://medical-dictionary.thefreedictionary. com/polypragmasy

3. Fedonyuk L. Ya., Oleshchuk A. M., Sas L. M., Boyarchuk O. R., Mikolenko A. Z., Oryol Yu. N., Glushko K. T. Polypragmasy: from paediatrics tо geriatrics. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics) 2018; 13(1), 77–82.

4. Polypharmacy. https://www.merriam-webster.com/dictionary/ polypharmacy

5. Polypharmacy. https://en.wiktionary.org/wiki/polypharmacy

6. Ross S. M. Defining Polypharmacy and Understanding Its Risks and Benefits. https://blog.cureatr. com/defining-polypharmacy-and-understanding- its-risks-and-benefits

7. Farmakos. https://cs.wikipedia.org/wiki/Farmakos

8. Pharmakon (philosophy). https://en.wikipedia.org/wiki/ Pharmakon_(philosophy)

9. Belz G. G., Palm D. Paracelsus. Dtsch. Ärztebl. 1993; 90(22), A 1630–1631.

10. Benzenhöfer U. In allen Bereichen begehrte er gegen die Autoritäten auf. Zum „500“ Geburtstag des Theophrast von Hohenheim, genannt Paracelsus. Dtsch Ärztebl. 1993; 90(10, 12), 704–706.

11. Khaitovych M. V. Polypharmacy: definition, risks, management. Oral and General Health 2021; 2(3), 7–12.

12. Komjáthy H. Vplyv farmakoterapie na starších pacientov. Prakt. lekárn. 2020; 10(1–2), 13–16.

13. Kriška M., Dukát A., Gajdošík J., Bernadič M. Polyfarmácia, polypragmázia, hyperpreskripcia – sú aj na Slovensku! Aktuálna úloha – depreskripcia. Monitor medicíny SLS 2020; 1–2, 5–9.

14. Varghese D., Ishida C., Haseer Koya H. Polypharmacy. 2022 In: StatPearls [Internet]. Treasure Island (FL): Stat- Pearls Publishing. https://www.ncbi.nlm.nih.gov/books/ NBK532953/#!po=5.55556

15. Duerden M., Payne R. Polypharmacy – what is it and how common is it? Prescriber 2014; 25(21), 44–47.

16. Newnham W. Remarks on the present aspect of medicine. Prov. Med. Surg. J. 1848; 12(11), 281–285.

17. Polypharmacy. https://www.ncbi.nlm.nih.gov/mesh/ ?term=POLYPHARMACY

18. A glossary of terms for Community Health Care and Services for Older Persons. WHO Centre for Health Development (Kobe, Japan)2004.

19. Montamat S. C., Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly. Clin. Geriatr. Med. 1992; 8(1), 143–158.

20. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G. E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1), 230.

21. Bakaki P. M., Horace A., Dawson N., Winterstein A., Waldron J., Staley J., Pestana Knight E. M., Meropol S. B., Liu R., Johnson H., Golchin N., Feinstein J. A., Bolen S. D., Kleinman L. C. Defining pediatric polypharmacy: A scoping review. PLoS ONE 2018; 13(11), e0208047.

22. Medication Safety in Polypharmacy. Geneva: World Health Organization 2019, 61 s. https://apps.who.int/ iris/bitstream/handle/10665/325454/WHO-UHC-SDS- 2019.11-eng.pdf?ua=1

23. Taghy N., Cambon L., Cohen J.-M., Dussart C. Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts – Results of a Literature Review. Ther. Clin. Risk Manag. 2020; 16, 57–73.

24. Duerden M., Avery T., Payn R. Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund 2013; 56 s. https://www.kingsfund.org.uk/ publications/polypharmacy-and-medicines-optimisation

25. Werder S. F., Preskorn S. H. Managing polypharmacy: Walking the fine line between help and harm. Curr. Psychiatr. 2003; 2(2), 24–36.

26. Polypharmacy and Maslow theory. https://www.eddusaver. com/polypharmacy-and-maslow-theory/

27. Scott I. A., Hilmer S. N., Reeve E., Potter K., Le Couteur D., Rigby D., Gnjidic D., Del Mar C. B., Roughead E. E., Page A., Jansen J., Martin J. H. Reducing inappropriate Polypharmacy. The Process of Deprescribing. JAMA Intern. Med. 2015; 175(5), 827–834.

28. Bushardt R. L., Massey E. B., Simpson T. W., Ariail J. C., Simpson K. N. Polypharmacy: misleading, but manageable. Clin. Interv. Aging 2008; 3(2), 383–389.

29. Bushardt R. L., Jones K. W. Nine key questions to address polypharmacy in the elderly. JAAPA 2005; 18(5), 32–37.

30. Lee G. B., Etherton-Beer Ch., Hosking S. M., Pasco J. A., Page A. T. The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review. Ther. Adv. Drug Saf. 2022; 13, 1–41.

31. Scottish Government Model of Care Polypharmacy Working Group. Polypharmacy Guidance, Realistic Prescribing, 3rd edition, 2018. Scottish Government, 83 s. https://www.therapeutics.scot.nhs.uk/wp-content/uploads/ 2018/04/Polypharmacy-Guidance-2018.pdf

32. Selph Ch., Cosca B. Less is More: Preventing Polypharmacy in Individuals with Intellectual Disabilities. https://publications. ici.umn.edu/impact/29-1/less-is-more-preventing-polypharmacy- in-individuals-with-intellectual-disabilities

33. Bricker D. A., Metzger A. H. Reducing Polypharmacy: Prudent Prescribing in Primary Care. Primary Care Reports. September 1st, 2009. https://www.reliasmedia. com/articles/114063-reducing-polypharmacy-prudent- prescribing-in-primary-care

34. Medication Without Harm – Global Patient Safety Challenge on Medication Safety. Geneva: World Health Organization 2017

35. Farrell B. J., Jeffs L., Irving H., McCarthy L. M. Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study. BMC Geriatr. 2020; 20, 368.

36. Rochon P. A., Gurwitz J. H. Drug therapy. Lancet 1995; 346(8966), 32–36.

37. Rochon P. A., Gurwitz J. H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315(7115), 1096–1099.

38. Rochon P. A., Gurwitz J. H. The prescribing cascade revisited. Lancet 2017; 389(10081), 1778–1780.

39. Scott I., Anderson K., Freeman C. Review of structured guides for deprescribing. Eur. J. Hosp. Pharm. 2017; 24(1), 51–57.

40. Scott I. A., Le Couteur D. G. Physicians need to take the lead in deprescribing. Intern. Med. J. 2015; 45(3), 352– 356.

41. McCarthy L. M., Visentin J. D., Rochon P. A. Assessing the Scope and Appropriateness of Prescribing Cascades. J. Am. Geriatr. Soc. 2019; 67(5), 1023–1026.

42. Mair A., Fernandez-Llimos F., Alonso A., Harrison C., Hurding S., Kempen T., Kinnear M., Michael N., McIntosh J., Wilson M. Polypharmacy Management by 2030: a patient safety challenge. 2nd edition Coimbra: SIMPATHY Consortium 2017.